Events - 30 Mar 13:00FDA public meeting on vitiligo

Event

Silver Spring, MD, USA

Due to extenuating circumstances, this meeting is postponed until further notice.

US Federal Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo.

The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment.

You can participate in three ways: 

  1. Register, attend the meeting and take active part in discussions.
  2. Join webcast and comment throughout the live stream.
  3. Submit your online comments before the meeting.

WHEN: Monday, March 30, 2020 at 1 p.m. to 5 p.m.

WHERE: FDA White Oak Campus 10903 New Hampshire Ave. Building 31, Great Room Silver Spring, MD 20903

Discussion questions

FAQOther Questions

  • Vitiligo and hearing loss: any connection?

    In short, NO. Recent research shows no relationship between a degree of skin depigmentation and hearing loss severity in vitiligo patients. The results of this study showed tha...

  • I have vitiligo: will my children have vitiligo, too?

    Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...

  • What causes vitiligo?

    Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...